Who knew? Who knew?
And McKesson, plus a boat load of other DM, PBM and pharma-related companies (like Pfizer Health Solutions) are bugging patients to take their pills, and increasing pharma company profits into the bargain. And even after digging up David Sobel, John Abramson & Jerry Avorn, the NYT can’t find too much bad to be said about these programs — even though pharma companies are paying for them. Everyone agrees compliance is good, and getting patients to take their pills is hard work.
But I didn’t notice them referring to any compliance programs for generics. Funny that.